Breastlink is committed to working with research partners to help improve our ability to detect and treat breast cancer. Breast cancer research news from our practices
Breastlink Partners with Researchers to Explore Atezolizumab in Triple-Negative Breast Cancer Patients
Breastlink has partnered with researchers to explore an investigational cancer immunotherapy called atezolizumab (MPDL3280A) in the treatment of metastatic triple-negative breast cancer. In early-stage trials, atezolizmab was effective in patients previously treated for triple-negative breast cancer. A new trial will investigate atezolizumab with chemotherapy in metastatic triple-negative breast cancer patients who have not received prior systemic therapy for incurable disease. […]
The Annual Meeting of the American Society of Clinical Oncology (ASCO) provides an opportunity for thousands of oncologists and healthcare professionals to receive research updates and exchange ideas surrounding trends in cancer treatments. More than 30,000 attend each year, making it one of the largest educational and scientific conferences dedicated to advancing cancer care. I recently joined my colleagues for the ASCO 2015 Annual Meeting, where a focus was on breakthroughs in immunotherapy.
What is Immunotherapy?
Immunotherapy refers to treatments that prompt the human body’s immune system to attack cancer cells. Cancer occurs when a genetic mutations occurs that causes a healthy cell to become cancerous. Can the immune system recognize these […]
The landscape of testing for hereditary cancer predisposition genes has been in rapid evolution. Recently developed tests can evaluate up to 43 genetic mutations associated with increased risk for a variety of cancers including breast cancer. Using data collected from our clinics, my Breastlink colleagues and I have analyzed how safe and effective these newer multi-gene tests are in comparison to previous methods of genetic testing.
The Development of Multi-Gene Tests for Breast Cancer Risk
Two key events have helped change the face of genetic testing:
- Technology became so advanced with next generation sequencing that it became as simple […]
As the 37th annual San Antonio Breast Cancer Symposium (SABCS) drew to a close, a range of intriguing clinical observations and long-awaited trial updates had made the event a valuable experience for investigators and attendees alike. Among some of the most interesting updates, in my opinion, were advancements in treatments for estrogen receptor-positive (ER-positive) breast cancer, premenopausal breast cancers and advanced breast cancers.
ER Positive Breast Cancers
Results from the FERGI trial were presented at this year’s meeting. This trial is investigating the new agent pictilisib, which belong to a new class of drugs called PI3K inhibitors that […]
This year at the San Antonio Breast Cancer Symposium (SABCS) there were two aspects of breast cancer that were clearly emphasized: use of ovarian suppression in premenopausal women with breast cancer and advances in genetic testing for hereditary cancer predisposition.
Results of the SOFT trial (further detailed by Dr. Wade Smith in this post), show a clear benefit to the addition of ovarian suppression in women under the age of 35. This benefit resembles that seen with the addition of Herceptin for HER2+ cancer, and now calls for a change in practice management.
The second “call for action” released […]
Every year, some of the world’s leading experts on breast cancer gather for the San Antonio Breast Cancer Symposium (SABCS). One of the premier forums on the subject, SABCS offers physicians and allied health professionals an environment conducive to the exchange of ideas and discussion around current trends in breast cancer research.
This is an excellent opportunity to meet with others passionate about breast health care, as well as to learn about new ways we can help patients. At this year’s SABCS, I am excited to learn more about the results of a trial investigating the use of radiation therapy, new markers for identifying cancer in the blood, advances in genetic […]
The San Antonio Breast Cancer Symposium (SABCS) is one of the world’s premier forums on breast cancer prevention, screening and treatments. Leading experts on breast cancer from various backgrounds gather every year at the SABCS in an effort to promote discussion and education around current trends in breast cancer research.
Now in its 37th year, one of the major focuses of the 2014 SABCS will be on estrogen receptor positive breast cancer. For those interested in developments in this area and others, here is what to watch for.
Estrogen Receptor Positive Breast Cancers
In year’s past, HER2-positive breast cancers have […]
A recent study revealed great news for women facing early-stage invasive breast cancer: choosing to preserve some breast tissue rather than removing the entire breast isn’t inviting more risk.
Survival Rate is Higher with Lumpectomy vs Mastectomy
Even when coupled with various factors – age, socioeconomic status, race, tumor grade, proportion of positive nodes and year of diagnosis – women were less likely to die with a lumpectomy.
For decades, the two […]
First Annual CRC Charity Golf Tournament
The Importance of Breast Cancer Research: proceeds of the first Cancer Research Collaboration Charity (CRC) Golf Tournament will be used to support ongoing efforts of the CRC and its partners to fight cancer.
The Cancer Research Collaboration is currently preparing to host its first annual CRC Charity Golf Tournament in Mission Viejo. A great chance for golfers to play a round while supporting a worthy cause and for other supporters to engage during a dinner reception, the event is sure to be a hit.
However, while we wait for the fun to begin, it is important to take a moment to remember why […]
Recent research into modern breast cancer therapies have driven major breakthroughs in antibody-drug conjugates, or “smart drugs,” which work by targeting cancer cells while minimizing damage to healthy body tissue.
Kadcyla, also known ado-trastuzumab emtansine (T-DM1), is one of the latest “smart drugs” to be FDA-approved in the treatment of women diagnosed with metastatic HER2-positive breast cancer. Kadcyla may also have potential as therapy after surgery where intent is curative.
Breastlink participated in the EMILIA trial, a key clinical trial that helped lead to swift approval of Kadcyla for HER2-positive advanced breast cancer. We also are participating in other ongoing trials to investigate additional uses for Kadcyla in […]